GeneThera
OTC Bulletin Board : GTHA

GeneThera

July 11, 2005 09:01 ET

GeneThera Grants First Right of Refusal to Ante-Mortem Animal Disease Diagnostics

WHEAT RIDGE, Colo.--(CCNMatthews - Jul 11, 2005) -

GeneThera, Inc. (OTCBB:GTHA) has granted Beckman Coulter, Inc. (NYSE:BEC) the first right of refusal to license GeneThera's patented technology for the development of ante-mortem animal diagnostic tests. This is part of a collaboration reached between the two companies allowing GeneThera and Beckman Coulter to share data pertaining to the validation of GeneThera's live animal blood tests for several animal diseases.

Dr. Antonio Milici, M.D., Ph.D. commented, "This is a significant milestone for GeneThera. Beckman Coulter is one of the world's leading manufacturers of biomedical testing systems, tests and supplies. Our collaboration will unite the expertise of Beckman Coulter with the cutting edge technology of GeneThera."

"We are looking forward to working with GeneThera to identify commercial applications of their technology," stated Chris Neary, General Manager, Prion Business Center, Beckman Coulter, Inc.

About GeneThera:

GeneThera, Inc. is a molecular biotechnology company located in Wheat Ridge, CO. The Company provides genetic diagnostic solutions for the veterinary and agricultural industries with future plans to include the health-care industry. The Company's proprietary diagnostic solution is based on a genetic expression assay, GEA™, a protocol designed to function on a highly automated Fluorogenic PCR platform. This platform enables GeneThera to offer tests that are presently not available from other technologies. The GEA is designed for a host of individual diseases, the current priority being Chronic Wasting Disease, a disease affecting elk and deer in North America; E.Coli 0157:H7 and Johne's Disease, diseases affecting cattle worldwide. Future plans include all infectious disease potentially affecting domesticated livestock as well wildlife intended for human consumption, particular priority being given to Mad Cow and Foot & Mouth diseases in cattle.

"Safe Harbor" Statement: Certain statements in this release are "forward-looking" statements as defined in the Private Securities Litigation Reform Act of 1995. Such statements are subject to numerous risks and uncertainties. Actual results may vary significantly from the results expressed or implied in such statements. Factors that could cause actual results to materially differ from forward-looking statements include, but are not limited to, the Company's ability to meet the terms and conditions required to obtain its project financing, risks and delays associated with product development, risk of market acceptance of new products, risk of technology or product obsolescence, competitive risks, reliance on development partners and the need for additional capital.

Contact Information